News and Announcements
Sentiment Index Results 2017
- Published March 14, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Capital Insights
Wholesale Investor would like to present the results of the Investor Sentiment Index 2017.
The survey covers a range of topics and issues, which will assist us to understand the general sentiment of investors, types of opportunities you are currently seeking and the lessons you have learnt.
A few statistics from the Index are as follows; The majority of Wholesale Investor subscribers were interested into investing in South-east Asian opportunities with most seeking opportunities into Pre-IPO Opportunities. Most investors believe that Biotech/ Medical Services will have the most growth during 2017. Three top attributes investors are in quest of Unique, Competitive advantage when assessing small cap listed companies. Most concerns that arise when investing into overseas markets is Political instability.
To see more results please see the infographs below.
Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
